An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 021829
Company: UCB INC

Products on NDA 21829

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
NEUPRO	ROTIGOTINE	2MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	Yes
NEUPRO	ROTIGOTINE	4MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
NEUPRO	ROTIGOTINE	6MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
NEUPRO	ROTIGOTINE	1MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
NEUPRO	ROTIGOTINE	3MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
NEUPRO	ROTIGOTINE	8MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No

Labels for NDA 021829

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
07/12/2021	SUPPL-22	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021829s021s022lbl.pdf
07/12/2021	SUPPL-22	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021829s021s022lbl.pdf
07/12/2021	SUPPL-21	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021829s021s022lbl.pdf
04/24/2020	SUPPL-17	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021829s017lbl.pdf
04/03/2020	SUPPL-19	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021829s019lbl.pdf
04/03/2020	SUPPL-19	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021829s019lbl.pdf
01/18/2019	SUPPL-16	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021829s016lbl.pdf
11/29/2018	SUPPL-15	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021829s015lbl.pdf
11/29/2018	SUPPL-15	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021829s015lbl.pdf
02/26/2015	SUPPL-7	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021829s007lbl.pdf
04/02/2012	SUPPL-2	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
04/02/2012	SUPPL-1	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s001lbl.pdf
05/09/2007	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021829lbl.pdf

Top